Boehringer Ingelheim is a world-leading, research-driven biopharmaceutical company. Making new and better medicines for patients is at the heart of what we do. Independent and family-owned, we have the freedom to pursue our long-term vision, identifying the health challenges of the future and targeting those areas of need where we can do the most good. In 2023 Boehringer Ingelheim achieved net sales of 25.6 billion euros, with an industry-leading investment in R&D of 22.5% of net sales. Our vision is powered by innovation. And our industry-leading investment in R&D drives this, with a portfolio that is anchored by more than 60 new medical entities, enabling the next generation of breakthrough medicines.